• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Marker Therapeutics Inc.

    3/20/26 4:08:49 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRKR alert in real time by email
    DEFA14A 1 tm261499d5_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.)

     

    Filed by the Registrant x  
       
    Filed by a party other than the Registrant ¨  

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement
       
    ¨ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨ Definitive Proxy Statement
       
    x Definitive Additional Materials
       
    ¨ Soliciting Material Pursuant to §240.14a-12

     

    Marker Therapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x No Fee Required
       
    ¨ Fee paid previously with preliminary materials.
       
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

    Get informed before you vote *If you choose to vote these shares in person at the meeting, you must request a “legal proxy.” To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number Your Vote Counts! FLASHID-JOB# For complete information and to vote, visit www.ProxyVote.com Control # Ricky Campana P.O. Box 123456 Suite 500 51 Mercedes Way Edgewood, NY 11717 148,294 322,224 1 OF 2 30# Hextone, Inc. P.O. Box 9142 Farmingdale, NY 11735 XXXX XXXX XXXX XXXX MARKER THERAPEUTICS, INC. 2026 Annual Meeting Vote by April 30, 2026 11:59 PM ET You invested in MARKER THERAPEUTICS, INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on May 01, 2026. View the Proxy Statement, Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 19, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote in Person at the Meeting* May 01, 2026 9:00 AM CST Annual Meeting to be held virtually Beneficial Holder at the below URL: https://web.viewproxy.com/markertherapeutics/2026AM

    Voting Items Board Recommends THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com FLASHID-JOB# Control # XXXX XXXX XXXX XXXX 1.00000 322,224 148,294 Under New York Stock Exchange rules, brokers may vote “routine” matters at their discretion if your voting instructions are not communicated to us at least 10 days before the meeting. We will nevertheless follow your instructions, even if the broker’s discretionary vote has already been given, provided your instructions are received prior to the meeting date. MARKER THERAPEUTICS, INC. 2026 Annual Meeting Vote by April 30, 2026 11:59 PM ET 1. Election of Directors Nominees: 01 David Eansor 03 Juan Vera 05 Kathryn Penkus Corzo 02 Steven Elms 04 Katharine Knobil For 2 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement. For 3 To approve the adoption of an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of our Common Stock from 30,000,000 shares of Common Stock to 130,000,000 shares of Common Stock. For 4 To approve the adoption of an amendment to our Certificate of Incorporation, as amended, to revise the voting threshold required for an increase or decrease of Common Stock. For 5 To ratify the selection by the Audit Committee of the Board of Directors of CBIZ CPAs P.C. (CBIZ) as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. For 6 To approve the adjournment of the Annual Meeting in the event that the number of shares of Common Stock present or represented by proxy at the Annual Meeting and voting FOR the adoption of Proposal 3 is insufficient. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

     

    Get the next $MRKR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRKR

    DatePrice TargetRatingAnalyst
    3/5/2025$8.00Buy
    Canaccord Genuity
    2/17/2022$3.00 → $1.00Buy → Neutral
    Roth Capital
    More analyst ratings

    $MRKR
    SEC Filings

    View All

    SEC Form DEFA14A filed by Marker Therapeutics Inc.

    DEFA14A - Marker Therapeutics, Inc. (0001094038) (Filer)

    3/20/26 4:08:49 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Marker Therapeutics Inc.

    DEF 14A - Marker Therapeutics, Inc. (0001094038) (Filer)

    3/20/26 4:05:49 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Marker Therapeutics Inc.

    10-K - Marker Therapeutics, Inc. (0001094038) (Filer)

    3/18/26 5:26:35 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Marker International with a new price target

    Canaccord Genuity initiated coverage of Marker International with a rating of Buy and set a new price target of $8.00

    3/5/25 7:37:58 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marker Therapeutics downgraded by Roth Capital with a new price target

    Roth Capital downgraded Marker Therapeutics from Buy to Neutral and set a new price target of $1.00 from $3.00 previously

    2/17/22 6:14:24 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Marker Therapeutics with a new price target

    Piper Sandler initiated coverage of Marker Therapeutics with a rating of Overweight and set a new price target of $6.00

    3/25/21 6:18:22 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Knobil Katharine

    4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

    11/19/25 4:18:31 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Eansor Norman David

    4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

    11/19/25 4:10:21 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Elms Steve

    4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

    11/19/25 4:01:15 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Elms Steve bought $35,472 worth of shares (11,085 units at $3.20) (SEC Form 4)

    4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

    12/26/24 4:01:17 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner New Enterprise Associates 16, L.P. bought $1,773,600 worth of shares (554,250 units at $3.20) (SEC Form 4)

    4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

    12/23/24 4:40:48 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRKR
    Leadership Updates

    Live Leadership Updates

    View All

    Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

    Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer Strengthened manufacturing capabilities through collaboration with Cellipont Bioservices and expanded Board of Directors with appointment of Kathryn Penkus Corzo HOUSTON, March 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, today a

    3/18/26 5:31:30 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

    HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company's Board of Directors, effective November 1, 2025. Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent board director with more than 30 years of global leadership spanning R&D, clinical trials, regulatory approvals, commercialization, and corporate strategy across multiple therapeutic modalities and in

    11/5/25 7:30:00 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

    HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by Demy-Colton in collaboration with the WBB Research Institute titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?". The virtual event is scheduled to take place on May 28, 2025, at 11:00 a.m. EDT. This one-hour virtual event will feature insights from leading voices in the cell therapy space, f

    5/19/25 8:00:12 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRKR
    Financials

    Live finance-specific insights

    View All

    Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

    Results from safety lead-in stage of Marker's Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading New T cell manufacturing process for MT-401 and other product candidates designed to improve potency, increase antigen specificity and diversity and significantly reduce manufacturing time Company announces clinical updates, including plans to file additional INDs by year end, with clinical trials in solid tumors and blood cancers to be initiated in 2023 Company to host conference call and webcast at 5:00 p.m. EST today HOUSTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, In

    2/16/22 4:30:00 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

    HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, February 16, 2022 at 5:00 p.m. EST to provide an update on the Company's clinical programs, manufacturing processes and pipeline. The webcast will be accessible in the Investors section of the Company's website at www.markertherapeutics.com. Individuals can participate in the conference call by dialing 877-869-3847 (domestic) or 201-68

    2/8/22 4:05:00 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

    HOUSTON, Nov. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.   "This quarter, we continued our momentum in advancing Marker's Phase 2 trial of MT-401, Marker's lead MultiTAA-specific T cell therapy, for the treatment of post-transplant acute myeloid leu

    11/10/21 4:05:00 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Marker Therapeutics Inc. (Amendment)

    SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

    5/17/24 6:25:14 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Marker Therapeutics, Inc.

    SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

    3/26/21 10:38:04 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Marker Therapeutics, Inc.

    SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

    3/15/21 4:45:13 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

    Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine highlighted promising results of multi-antigen targeted T cells in pancreatic cancer Strengthened manufacturing capabilities through collaboration with Cellipont Bioservices and expanded Board of Directors with appointment of Kathryn Penkus Corzo HOUSTON, March 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors, today a

    3/18/26 5:31:30 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

    HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026. Presentation Details: Event:Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDate: Wednesday, February 25, 2026Time: 8:00 – 8:30 a.m. ESTTrack: Track 3Webcast Link: "Events and Presentations" section on Marker's IR

    2/18/26 8:00:00 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics' MAR-T Cell Technology

    HOUSTON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company with the worldwide exclusive license of Multi-Antigen Targeted T cells (also referred to as Multi-Antigen Recognizing T cells, or MAR-T cells, by Marker), a technology developed at Baylor College of Medicine for the treatment of hematologic and solid tumors, today announced that Baylor College of Medicine's TACTOPS clinical study in pancreatic cancer was featured on Good Morning America on Thursday, January 22, 2026. The segment spotlighted the Baylor-led research recently published in Nature Medicine evaluating autologous Multi-Antigen Targeted T cell therapy in pa

    1/26/26 7:00:00 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care